Log In
person
Genmab A/S
GNMSF
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (DKK) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (DKK) | Percentage |
| Pharmaceutical Products |
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
14.01B | 85.06% |
| Pharmaceutical Products |
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
2.46B | 14.94% |
| keyboard_arrow_down |
Pharmaceutical Products
Pharmaceutical Patent Licensing
|
14.01B | 85.06% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||
| keyboard_arrow_down |
Pharmaceutical Products
Pre-Revenue Pharmaceuticals
|
2.46B | 14.94% |
| keyboard_arrow_right |
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
||